Huang Bao-Tian, Wu Li-Li, Guo Long-Jia, Xu Liang-Yu, Huang Rui-Hong, Lin Pei-Xian, Chen Jian-Zhou, Li De-Rui, Chen Chuang-Zhen
Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou.
Department of Nosocomial Infection Management, The Second Affiliated Hospital of Shantou University Medical College, Shantou, People's Republic of China.
Onco Targets Ther. 2017 Apr 19;10:2209-2217. doi: 10.2147/OTT.S132388. eCollection 2017.
To compare the radiobiological response between simultaneously dose-escalated and non-escalated intensity-modulated radiation therapy (DE-IMRT and NE-IMRT) for patients with upper thoracic esophageal cancer (UTEC) using radiobiological evaluation.
Computed tomography simulation data sets for 25 patients pathologically diagnosed with primary UTEC were used in this study. DE-IMRT plan with an escalated dose of 64.8 Gy/28 fractions to the gross tumor volume (GTV) and involved lymph nodes from 25 patients pathologically diagnosed with primary UTEC, was compared to an NE-IMRT plan of 50.4 Gy/28 fractions. Dose-volume metrics, tumor control probability (TCP), and normal tissue complication probability for the lung and spinal cord were compared. In addition, the risk of acute esophageal toxicity (AET) and late esophageal toxicity (LET) were also analyzed.
Compared with NE-IMRT plan, we found the DE-IMRT plan resulted in a 14.6 Gy dose escalation to the GTV. The tumor control was predicted to increase by 31.8%, 39.1%, and 40.9% for three independent TCP models. The predicted incidence of radiation pneumonitis was similar (3.9% versus 3.6%), and the estimated risk of radiation-induced spinal cord injury was extremely low (<0.13%) in both groups. Regarding the esophageal toxicities, the estimated grade ≥2 and grade ≥3 AET predicted by the Kwint model were increased by 2.5% and 3.8%. Grade ≥2 AET predicted using the Wijsman model was increased by 14.9%. The predicted incidence of LET was low (<0.51%) in both groups.
Radiobiological evaluation reveals that the DE-IMRT dosing strategy is feasible for patients with UTEC, with significant gains in tumor control and minor or clinically acceptable increases in radiation-induced toxicities.
通过放射生物学评估,比较同步剂量递增和非递增调强放射治疗(DE-IMRT和NE-IMRT)在上段食管癌(UTEC)患者中的放射生物学反应。
本研究使用了25例经病理诊断为原发性UTEC患者的计算机断层扫描模拟数据集。将25例经病理诊断为原发性UTEC患者的GTV和受累淋巴结接受64.8 Gy/28次分割递增剂量的DE-IMRT计划与50.4 Gy/28次分割的NE-IMRT计划进行比较。比较剂量体积指标、肿瘤控制概率(TCP)以及肺和脊髓的正常组织并发症概率。此外,还分析了急性食管毒性(AET)和晚期食管毒性(LET)的风险。
与NE-IMRT计划相比,我们发现DE-IMRT计划使GTV的剂量递增了14.6 Gy。对于三个独立的TCP模型,肿瘤控制预计分别提高31.8%、39.1%和40.9%。两组的放射性肺炎预测发生率相似(3.9%对3.6%),且放射性脊髓损伤的估计风险极低(<0.13%)。关于食管毒性,Kwint模型预测的≥2级和≥3级AET估计分别增加了2.5%和3.8%。使用Wijsman模型预测的≥2级AET增加了14.9%。两组LET的预测发生率均较低(<0.51%)。
放射生物学评估表明,DE-IMRT给药策略对UTEC患者是可行的,在肿瘤控制方面有显著提高,且放射诱导毒性的增加轻微或在临床可接受范围内。